Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03150693 · ClinicalTrials.gov registry record · Phase 3
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 303
- Enrollment target
NCT03150693 is a Phase 3 study that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 303 participants.
The verdict
NCT03150693, a Phase 3 study, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 303 participants
- Enrollment target
Study Summary
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as \[intervention\], work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.
Interventions
- DRUG Dexamethasone
- DRUG Cytarabine
- DRUG Allopurinol
- DRUG Daunorubicin Hydrochloride
- DRUG Vincristine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03150693
The ClinicalTrials.gov registry entry for NCT03150693 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT03150693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03150693 about?
NCT03150693 is a clinical study titled "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia". This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy dr...
What is the current status of trial NCT03150693?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 303 participants. The study started on 2017-09-20. Estimated completion is 2027-08.
What interventions are being tested in trial NCT03150693?
The interventions under investigation include: Dexamethasone (DRUG), Cytarabine (DRUG), Allopurinol (DRUG), Daunorubicin Hydrochloride (DRUG), Vincristine Sulfate (DRUG).
Who is sponsoring clinical trial NCT03150693?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.